[194 Pages Report] The Continuous Glucose Monitoring Systems Market size was estimated at USD 5.54 billion in 2023 and expected to reach USD 6.21 billion in 2024, at a CAGR 12.37% to reach USD 12.55 billion by 2030.
Continuous Glucose Monitoring Systems (CGMS) are advanced medical devices designed to provide real-time glucose readings at regular intervals, typically every few minutes, 24/7. These systems comprise a small sensor that transmits the data wirelessly to a display device, which could be a dedicated receiver, a smartphone, or a smartwatch, enabling the user to monitor their glucose levels without the requirement of traditional fingerstick blood tests. The growing preponderance of diabetes across the globe and the rising awareness of the benefits of continuous glucose monitoring over traditional blood glucose monitoring are driving the market growth. However, devices' high prices and lack of uniform reimbursement can limit market penetration. Inaccuracies in glucose readings due to device calibration issues or interference from external factors also pose a challenge. Furthermore, leveraging big data and advanced analytics to improve predictive capabilities, personalization, and clinical outcomes creates potential opportunities for market growth.
The Americas, led by the United States and Canada, show a strong market for CGM systems, aided by higher purchasing power and well-established healthcare systems implementing the latest technologies. The United States & Canada are prominent in CGM technology, with numerous companies researching and developing new systems, evident from a high number of patents filed in this domain. Consumers in the United States have shown an inclination towards maintaining healthy lifestyles, integrating personal health technology with everyday living. There is significant investment and insurance coverage that promotes the use of CGM systems, making them more accessible to the population. European Union countries demonstrate a robust demand for CGM systems, broadly supported by widespread awareness, a push for lifestyle management of diabetes, and favorable insurance reimbursement scenarios. The European Union’s medical device sector is tightly regulated, ensuring high standards of product quality and safety. Countries including Germany, France, and the UK are leaders in the adoption of CGM systems. The Middle East, particularly the Gulf Cooperation Council (GCC) countries, has high per capita healthcare spending and is rapidly adopting advanced technologies in healthcare. Asia Pacific is undergoing a surge in the demand for CGM systems due to the increasing prevalence of diabetes and heightened awareness about the disease. The rising popularity of wearable technology for health monitoring indicates a broad consumer need for convenient and non-intrusive healthcare devices in the APAC region.
Integrated insulin pumps are devices that deliver insulin automatically based on the set basal rate and work in conjunction with continuous glucose monitoring (CGM) systems. They adjust the insulin delivery based on real-time glucose readings. This feature greatly contributes to the seamless management of blood glucose levels in diabetes patients, especially useful for those with intensive insulin therapy needs or those with Type 1 diabetes. Sensors are a crucial part of CGM systems, as they are the components that measure levels of glucose in the interstitial fluid beneath the skin. CGM sensors typically require changing every 7 to 14 days, depending on the model. Patients who desire minimal intrusion and longer wear times prefer sensors with extended life spans. The transmitter is the part of the CGM system that sends real-time glucose data from the sensor to a receiver and smart device. The receiver is the device that displays the glucose data. Some patients prioritize a system that allows the use of their own smartphone as a receiver, whereas others prefer a dedicated device if they are not comfortable using smart devices.
Continuous Glucose Monitoring (CGM) systems are crucial for the adult population, especially those diagnosed with Type 1 or Type 2 diabetes. Adults require consistent and accurate monitoring of their blood glucose levels to manage their condition effectively and to prevent acute and long-term complications associated with diabetes. CGM systems for children are designed with special considerations for size, sensitivity, and ease of use, owing to the unique physiological and lifestyle requirements of the pediatric population. These devices help parents and caregivers monitor and manage their child's diabetes more effectively, providing peace of mind and improved quality of life.
Patients with Type 1 diabetes rely on external insulin because of the autoimmune destruction of the insulin-producing beta cells in the pancreas. Continuous Glucose Monitoring (CGM) systems for this group provide convenience and crucial tools for the management of glucose levels. These patients need real-time data to adjust insulin doses accurately. CGM systems offer significant advantages over traditional blood glucose monitoring, providing detailed insights into glucose trends, which results in better glycemic control and reduction of hypoglycemia risk. Type 2 diabetes patients might not always require insulin but still need to monitor their glucose levels, especially if they are on sulfonylureas and meglitinides, which increase the risk of hypoglycemia. CGM for Type 2 diabetes is geared towards lifestyle management, including diet and exercise, alongside medication. The use of CGM is progressively becoming more common in this group as the technology becomes more affordable and as evidence mounts that it can help improve glycemic control in non-insulin-treated patients.
Diagnostic centers and clinics represent a significant segment for the deployment of Continuous Glucose Monitoring (CGM) systems. These facilities often serve as the initial point of contact for patients experiencing symptoms of diabetes and for those who require ongoing monitoring for their diagnosed condition. Home healthcare represents a rapidly growing segment for CGM systems, as an increasing number of patients with diabetes prefer to manage their condition in the comfort of their own homes. These devices offer convenience and allow for continuous monitoring without the need to visit a healthcare provider frequently. Intensive Care Units (ICUs) are critical settings wherein patients require constant and close monitoring, including for their glucose levels. CGM systems in ICUs must be highly reliable and capable of integrating with other monitoring equipment to ensure a holistic view of a patient's health status.
The market dynamics represent an ever-changing landscape of the Continuous Glucose Monitoring Systems Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Continuous Glucose Monitoring Systems Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Continuous Glucose Monitoring Systems Market.
The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Continuous Glucose Monitoring Systems Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.
The value chain of the Continuous Glucose Monitoring Systems Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.
The pricing analysis comprehensively evaluates how a product or service is priced within the Continuous Glucose Monitoring Systems Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Continuous Glucose Monitoring Systems Market.
The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Continuous Glucose Monitoring Systems Market.
The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Continuous Glucose Monitoring Systems Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.
The trade analysis of the Continuous Glucose Monitoring Systems Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.
The regulatory framework analysis for the Continuous Glucose Monitoring Systems Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Continuous Glucose Monitoring Systems Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Continuous Glucose Monitoring Systems Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Sibionics obtains CE Mark for GS1 continuous glucose monitoring system
Sibionics, a Chinese medical technology startup, has received the CE Mark for its pioneering GS1 Continuous Glucose Monitoring (CGM) system, signaling the green light for the system's sale and usage across the European market. This certification confirms the GS1 CGM's compliance with stringent EU standards for quality, safety, and performance, which are essential for consumer trust. [Published On: 2023-11-02]
Dexcom targets Americans with new CGM aimed at non-insulin-using diabetics
Dexcom is set to revolutionize the continuous glucose monitoring (CGM) market by unveiling a new device tailored for Americans living with Type 2 diabetes who do not require insulin therapy. This strategic move addresses a critical gap, highlighted by Dexcom's research, which is that a mere 5% of this demographic currently utilizes CGM technology. [Published On: 2023-06-26]
U.S. FDA Clears Abbott's Freestyle Libre 2 and Freestyle Libre 3 Sensors for Integration with Automated Insulin Delivery Systems
Abbott has announced FDA clearance for its next-generation FreeStyle Libre 2 and FreeStyle Libre 3 iCGM sensors, paving the way for their seamless integration with automated insulin delivery (AID) systems. Expanding their versatility, the improved sensors offer additional convenience and support for diabetes management by pairing them with insulin pumps to adjust insulin delivery automatically based on continuously monitored glucose levels. [Published On: 2023-03-06]
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Continuous Glucose Monitoring Systems Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
The report delves into recent significant developments in the Continuous Glucose Monitoring Systems Market, highlighting leading vendors and their innovative profiles. These include A. Menarini Diagnostics s.r.l, Abbott Laboratories, AgaMatrix Inc. by I-Sens Inc., Ascensia Diabetes Care Holdings AG, Dexcom, Inc., F. Hoffmann-La Roche Ltd., Insulet Corporation, Johnson & Johnson Services, Inc., Medtronic PLC, Medtrum Technologies Inc., Nemaura Medical Inc., Novo Nordisk A/S, NXP Semiconductors N.V., Senseonics Holdings Inc., Sibionics, STMicroelectronics N.V., Tandem Diabetes Care, Inc., Texas Instruments Incorporated, and Ypsomed Holding AG.
This research report categorizes the Continuous Glucose Monitoring Systems Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Component
- Integrated Insulin Pumps
- Sensors
- Transmitters & Receivers
- Demographics
- Adult Population
- Children Population
- Patient Type
- Type 1 Diabetes
- Type 2 Diabetes
- End User
- Diagnostic Centers & Clinics
- Home Healthcare
- ICUs
- Distribution Channel
- Institutional Sales
- Retail Sales
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
- Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
- Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
- Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
- Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
- Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.
- What is the current market size and projected growth?
- Which products, segments, applications, and regions offer promising investment opportunities?
- What are the prevailing technology trends and regulatory frameworks?
- What is the market share and positioning of the leading vendors?
- What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?
- Preface
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- Continuous Glucose Monitoring Systems Market, by Component
- Continuous Glucose Monitoring Systems Market, by Demographics
- Continuous Glucose Monitoring Systems Market, by Patient Type
- Continuous Glucose Monitoring Systems Market, by End User
- Continuous Glucose Monitoring Systems Market, by Distribution Channel
- Americas Continuous Glucose Monitoring Systems Market
- Asia-Pacific Continuous Glucose Monitoring Systems Market
- Europe, Middle East & Africa Continuous Glucose Monitoring Systems Market
- Competitive Landscape
- Competitive Portfolio
- List of Figures [Total: 26]
- List of Tables [Total: 460]
- List of Companies Mentioned [Total: 19]
CGM systems are advanced medical devices that record and display an individual's glucose levels continuously, especially for people with diabetes. These systems can measure glucose levels in real-time or at set intervals throughout the day, and the data is usually transmitted to a receiver or a mobile application, providing users with updates on glucose levels and trends. Unlike traditional blood glucose monitoring systems, CGMs provide more accurate and near-real-time measurements of glucose levels, making them incredibly useful for tracking blood sugar trends, identifying patterns in glucose levels, and making treatment decisions.
There are several CGM systems on the market today, such as standalone CGMs, which come with both a monitor and a transmitter, and integrated CGMs, which connect to insulin pumps. Some CGMs also come in adhesive patches attached to the skin and can transmit data to a smart device.
CGMs have several advantages that make them an essential tool in diabetes management. One significant advantage is that they help people with diabetes detect hypoglycemia or hyperglycemia early. This early warning allows for prompt intervention, reducing the risk of high and low blood sugar complications. Also, CGMs can provide insights into glucose patterns, assisting clinicians and patients in making informed decisions on diet, lifestyle, and medication.
Despite the advantages, CGMs have some disadvantages, including high cost, technical complexity, and discomfort associated with the insertion of the sensor and the need to calibrate the device. However, these limitations are gradually being addressed as technology advances, making CGMs more accessible and comfortable.
Continuous Glucose Monitoring Systems have revolutionized diabetes management, providing insights into glucose levels that were previously unattainable through traditional blood glucose monitoring. With more advanced and user-friendly CGM devices making their way into the market, there is no doubt that they will become a more common feature in diabetes management, potentially reducing the incidence of complications related to high and low blood sugar.
- How big is the Continuous Glucose Monitoring Systems Market?
- What is the Continuous Glucose Monitoring Systems Market growth?
- When do I get the report?
- In what format does this report get delivered to me?
- How long has 360iResearch been around?
- What if I have a question about your reports?
- Can I share this report with my team?
- Can I use your research in my presentation?